50 patents
Utility
Heterologous administration of tau vaccines
28 Feb 23
Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described.
Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
Filed: 23 Apr 20
Utility
Anti-tau Antibodies and Methods of Use
9 Feb 23
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
Filed: 22 Jun 22
Utility
Novel Molecules for Diagnosis
2 Feb 23
The present invention relates to novel amyloid-beta (abeta) binding molecules, in particular to abeta antibodies or antigen-binding fragments thereof and/or uses thereof.
Oskar Mario Adolfsson, Katarzyna Ewa Piorkowska
Filed: 10 Sep 20
Utility
Anti-Tau antibodies and methods of use
17 Jan 23
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
Filed: 3 Dec 20
Utility
Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy
27 Dec 22
A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.
Markus Mandler, Harald Weninger, Radmila Santic, Edith Kopinits
Filed: 11 Dec 19
Utility
Micro-Radiobinding Assays for Ligand Screening
15 Dec 22
The disclosure relates to binding assays that can measure the binding of ligands to a specific protein target in a micro-radiobinding assay.
Luigino Grasso
Filed: 30 Sep 20
Utility
Novel Compounds
1 Dec 22
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a component of the inflammasome pathway.
Emanuele GABELLIERI, Jerome MOLETTE
Filed: 22 Jun 20
Utility
Misfolded TDP-43 binding molecules
11 Oct 22
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43).
Tamara Seredenina, Oskar Adolfsson
Filed: 4 Jan 19
Utility
Anti-TDP-43 Binding Molecules and Uses Thereof
6 Oct 22
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43).
Tamara Seredenina, Tamar Magdalena Ziehm, Tariq Afroz
Filed: 22 May 20
Utility
Novel Molecules for Therapy and Diagnosis
22 Sep 22
The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (FDD)) or Diffuse Lewy Body Disease.
Elpida Tsika, John Warner, Romain Christian Ollier, Jan Peter Henning Stöhr
Filed: 17 Apr 20
Utility
Anti-Tau antibodies and methods of use
30 Aug 22
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
Filed: 5 Jun 20
Utility
Anti-abeta Vaccine Therapy
21 Jul 22
A liposomal vaccine composition comprising: a.
Andrea Pfeifer, Andreas Muhs (Deceased)
Filed: 20 May 20
Utility
Humanized Antibody
21 Jul 22
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Filed: 4 Aug 21
Utility
Anti-tau antibodies and methods of use
7 Jun 22
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Kristin Ruth Wildsmith, Marcel Van Der Brug, Andreas Muhs
Filed: 9 Oct 20
Utility
Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
28 Apr 22
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
Sreenivasachary Nampally, Emanuele Gabellieri
Filed: 29 Jan 20
Utility
Gamma-carboline compounds for the detection of Tau aggregates
19 Apr 22
Mathias Berndt, Andre Müller, Felix Oden, Hanno Schieferstein, Heribert Schmitt-Willich, Heiko Kroth, Jérôme Molette
Filed: 22 Jan 19
Utility
Misfolded TDP-43 Binding Molecules
27 Jan 22
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43).
Tamara Seredenina, Oskar Adolfsson
Filed: 4 Jan 19
Utility
Compositions of Phosphorylated Tau Peptides and Uses Thereof
16 Dec 21
Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described.
Elizabeth Anne Ramsburg, Anish Chakkumkal, David Hickman
Filed: 19 Aug 21
Utility
Anti-tau Antibodies and Methods of Use
28 Oct 21
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
Filed: 3 Dec 20
Utility
Humanized Antibody
14 Oct 21
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Filed: 16 Nov 20